A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid...
Major Depressive DisorderThis project will enable the investigators to conduct a randomized clinical trial to demonstrate the value of generalist care managers in the treatment of depression in Medicaid patients seen in primary health care practices. Depressed patients will be recruited at two primary care practices in Western North Carolina and randomly assigned to either generalist care management or usual care. Patients in each condition will be assessed at baseline and six months follow-up. Outcomes will include depressive symptoms, level of functioning, and cost-effectiveness measures.
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
Major Depressive DisorderThe purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive Disorder
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression...
Major Depressive DisorderPsychotic DisordersCorlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this study is to allow patients who have already participated in an earlier 8 week study of Corlux versus placebo (an inactive pill) to receive additional courses of treatment with Corlux periodically if a psychotic episode should reappear during a period of one year.
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
Major DepressionBipolar Disorder1 moreThe purpose of this project is to determine whether concurrent treatment of patients with major depression (unipolar or bipolar) with triiodothyronine (T3) and sertraline, will lead to a stronger and/or more rapid antidepressant effect than treatment with sertraline alone.
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation...
Major Depressive DisorderThe Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate duloxetine for other possible uses or for other medical or scientific purposes other than those currently proposed. Duloxetine might not have any good effects for you.
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
Major Depressive DisorderA clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
Major Depressive DisorderA clinical study to determine the efficacy and safety of an Treatment of MK0869 in the treatment of depression.
An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
Depressive DisorderMajorA Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
Depressive DisorderMajorA Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding...
Major Depressive DisorderThe purpose of this trial is to evaluate the efficacy and safety of risperidone versus placebo in subjects with Major Depressive Disorder with sub-optimal response to antidepressant therapy.